Scott Moomaw Sells 9,539 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) insider Scott Moomaw sold 9,539 shares of the firm’s stock in a transaction dated Monday, July 13th. The shares were sold at an average price of $71.51, for a total value of $682,133.89. Following the transaction, the insider owned 182,485 shares of the company’s stock, valued at approximately $13,049,502.35. The trade was a 4.97% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Price Performance

Shares of Liquidia stock opened at $77.75 on Thursday. The firm has a market cap of $6.91 billion, a PE ratio of 555.40 and a beta of 0.55. The stock has a 50 day moving average of $67.08 and a 200 day moving average of $47.81. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. Liquidia Corporation has a 12 month low of $14.04 and a 12 month high of $82.96.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. The business had revenue of $132.87 million for the quarter, compared to the consensus estimate of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The company’s revenue was up 4187.1% on a year-over-year basis. On average, research analysts expect that Liquidia Corporation will post 3.02 EPS for the current fiscal year.

Trending Headlines about Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia’s YUTREPIA patent case appears to be turning more favorable, and the company is also being highlighted for expanding its patent position around the drug. That improves the outlook for protecting its pulmonary hypertension franchise and supports the bullish case for the stock. Liquidia (LQDA) Expands YUTREPIA As Patent Case Turns More Favorable
• Neutral Sentiment: Brokerage coverage remains constructive overall, with Liquidia receiving a consensus “Moderate Buy” rating from analysts. That supports the stock’s longer-term outlook, but it is not a new catalyst on its own. Liquidia Corporation (NASDAQ:LQDA) Receives Consensus Rating of “Moderate Buy” from Brokerages
• Negative Sentiment: Several insiders, including the CEO, CFO, general counsel, CAO, and others, disclosed stock sales at about the same price level. The trades were made under pre-arranged 10b5-1 plans and tied to tax withholding from equity vesting, but the size and number of sales may still raise some investor caution. SEC filing – Roger Jeffs sale

Institutional Investors Weigh In On Liquidia

Institutional investors have recently made changes to their positions in the company. Farallon Capital Management LLC raised its position in Liquidia by 102.1% in the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock worth $194,783,000 after purchasing an additional 4,326,876 shares during the period. TCG Crossover Management LLC bought a new position in shares of Liquidia during the third quarter valued at approximately $38,887,000. MPM Bioimpact LLC raised its holdings in shares of Liquidia by 600.4% in the fourth quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock worth $48,316,000 after buying an additional 1,200,869 shares during the period. Voloridge Investment Management LLC purchased a new position in Liquidia during the 3rd quarter valued at $12,571,000. Finally, Bank of America Corp DE increased its stake in Liquidia by 18.7% in the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after purchasing an additional 360,372 shares during the period. Institutional investors own 64.54% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on LQDA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research report on Tuesday, April 21st. Zacks Research upgraded shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $60.00 price target on shares of Liquidia in a report on Monday, May 11th. Oppenheimer set a $75.00 price objective on Liquidia in a research note on Friday, June 5th. Finally, Wall Street Zen downgraded Liquidia from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 27th. Three investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $68.88.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).